Crazy Volume Spikes for: Agile Therapeutics, Inc. (NASDAQ:AGRX)

Agile Therapeutics, Inc. (NASDAQ:AGRX)

H.C. Wainwright Assumes Agile Therapeutics, Inc. (NASDAQ:AGRX)’s stock to Buy with the price target of $10. This rating was issued on 10/02/17. The stock recently closed its previous session at $0.84 by showing a percentage change of -6.16% from its previous day closing price of $0.89.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Agile Therapeutics, Inc. (NASDAQ:AGRX) in which H.C. Wainwright Initiates Coverage On Agile Therapeutics, Inc. (NASDAQ:AGRX) to Buy by settling a price target of $10 on 7/19/17. Cantor Fitzgerald Initiates Coverage on the stock to Buy on 1/08/16 with no specific Price Target. Noble Financial Initiates Coverage on the company’s stock to Buy on 12/30/15 by setting a price target of $16. FBR Capital Initiates Coverage on Agile Therapeutics, Inc. (NASDAQ:AGRX) to Outperform with a price target of $17.

Agile Therapeutics, Inc. (NASDAQ:AGRX) currently has a consensus Price Target of $3. While some analysts have a High Price target for the stock of $4 and a Low Price Target of $2.

Several sell side analysts reviewed their recommendations on Agile Therapeutics, Inc. (NASDAQ:AGRX) where 0 analyst have rated the stock as Strong Buy, 3 analysts said it’s a Buy, 2 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 2.33. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Agile Therapeutics, Inc. (NASDAQ:AGRX) reported its Actual EPS of $-0.16/share. The analysts offering Earnings Estimates for the company were believing that Agile Therapeutics, Inc. (NASDAQ:AGRX) could bring EPS of $-0.17/share. The difference between Actual EPS and Estimated EPS was 0.01 Percent. Thus the company showed an Earnings Surprise of 5.9 Percent.

Agile Therapeutics, Inc. (NASDAQ:AGRX) has a market capitalization of 28.71 Million. The stock traded with the volume of 2.66 Million shares in the last trading session. The stock touched its high share price of $5.33 on 11/27/17 and the stock also touched its Lowest price in the last 52-weeks of trading on 08/13/18 as $0.23. The company has a 1 Year high price target of $6. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of 58.85%. The Moving Average SMA50 is 110.34% while SMA200 is -51.19%.

Agile Therapeutics, Inc. (NASDAQ:AGRX) is currently showing its ROA (Return on Assets) of -54.1%. The Return on Investment (ROI) is at 0% while it’s Return on Equity (ROE) value stands at -75.8%. The stock currently shows its YTD (Year to Date) performance of -68.95 percent while its Weekly performance value is 36.92%. The Monthly and Yearly performances are 148.5 percent and -83.46 percent respectively. The Relative Volume value measured for Agile Therapeutics, Inc. (NASDAQ:AGRX) is 0.63. The Average Volume (3 months) is 4.22 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. AGRX has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 1.05 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company’s lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.